(Q37321292)

English

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study

scientific article published on 26 July 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

0 references

0 references

author name string

R Terkeltaub

1

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

J S Sundy

2

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

H R Schumacher

3

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

F Murphy

4

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

S Bookbinder

5

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

S Biedermann

6

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

R Wu

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

S Mellis

8

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

A Radin

9

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

language of work or name

0 references

publication date

26 July 2009

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

68

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

10

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

1613-1617

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732898

6 September 2017

The role of interleukin-1 and the inflammasome in gout: implications for therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732898

6 September 2017

Assessment of outcome in clinical trials of gout - a review of current measures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732898

6 September 2017

The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732898

6 September 2017

A pilot study of IL-1 inhibition by anakinra in acute gout

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732898

6 September 2017

The inflammatory process of gout and its treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732898

6 September 2017

Gout-associated uric acid crystals activate the NALP3 inflammasome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732898

6 September 2017

Safety and pharmacokinetics of subcutaneously administered rilonacept in patients with well-controlled end-stage renal disease (ESRD).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732898

26 June 2018

Quality of life and disability in patients with treatment-failure gout.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732898

2 September 2018

Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732898

2 September 2018

Treatment-failure gout: a moving target

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732898

2 September 2018

The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732898

2 September 2018

Clinical practice. Gout

1 reference

https://pubmed.ncbi.nlm.nih.gov/19635719

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/ARD.2009.108936

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37321292&oldid=2122806891"